• Curanex posted a net loss of USD 3.15 million for Q1 ended March 31, 2026, widening from a loss of USD 137,583 a year earlier, while reporting no revenue.
• General and administrative expense climbed to USD 927,197 from USD 137,452, driven by higher personnel-related costs and higher public-company professional fees.
• Research and development expense rose to USD 2.26 million as it continued IND-related studies, with prepaid R&D at USD 3.9 million for advance payments to CROs and CDMOs.
• Cash and cash equivalents totaled USD 4.02 million at March 31, 2026, versus USD 198,943 a year earlier, following about USD 15.3 million in net IPO proceeds received in 2025.
• Recent milestones included completion of a GMP pilot-scale batch of Phyto-N in February and a 28-day dose-range finding toxicology study in March, keeping the program on track for a planned ulcerative colitis IND submission in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curanex Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022892), on May 14, 2026, and is solely responsible for the information contained therein.